By bringing a safe, ambulatory and non-invasive solution to patients with #prostate conditions, watch how EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold.

EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold. Read more

Final US 2021 reimbursement rules for High Intensity Focused Ultrasound (HIFU)

U.S. Centers for Medicare and Medicaid Services (CMS) has issued its final rules establishing, for the first time, a Category 1 CPT code which facilitates reimbursement for the ablation of malignant prostate tissue with HIFU technology, effective January 1, 2021. Read more

First patients treated in phase 2 study of Focal One for the treatment of deep invasive endometriosis

the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Read more

Approval received for phase II study evaluating HIFU for deep invasive endometriosis

EDAP TMS has received approval from French health authorities to initiate a Phase II multicenter clinical trial evaluating its Focal One® HIFU to treat deep rectal endometriosis. Read more

Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology

Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more

Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology

Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more

EDAP Announces Recent Focal One Sales Successes

Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution.

Read more

EDAP announces exclusive worldwide distribution rights to EXACT Imaging's Micro-Ultrasound Technologies

EDAP announces exclusive worldwide distribution rights to EXACT Imaging's Micro-Ultrasound Technologies

Read more

B Riley FBR Initiates Research Coverage on EDAP TMS

Last week Andrew D’Silva of B Riley FBR launched research coverage on EDAP TMS with a buy-rating and price target at $5.50. Read more

EDAP TMS about COVID-19

Update on COVID-19 and the Potential Impact to Operations

Read more